Semin Thromb Hemost 2001; 27(3): 253-268
DOI: 10.1055/s-2001-15255
Copyright © 2001 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Acute Immune Thrombocytopenia (ITP) in Childhood: Retrospective and Prospective Survey in Germany

Anton H. Sutor, Anja Harms, Klaus Kaufmehl
  • Universitäts-Kinderklinik, Freiburg, Germany
Further Information

Publication History

Publication Date:
31 December 2001 (online)

ABSTRACT

Treatment of acute childhood immune thrombocytopenia (ITP) is controversial. For information on the present situation in Germany, a retrospective and a prospective survey were carried out. In the retrospective survey, questionnaires were sent to all German pediatric hospitals asking about local policies for handling ITP and whether in the preceding year (starting on October 1995) death or ICH had occurred; 86% answered. In the prospective survey, 94% responded to the mailings (``have you seen a case of ITP?'') sent in monthly intervals between October 1, 1996 and September 30, 1997; 89% of the questionnaires were retrieved. In the retrospective survey, no deaths and no ICH were reported. If only mild bleedings, such as skin bleeds alone (or additional mild mucous membrane bleeding) were present, 20.5% (26.4%) preferred the ``watchful waiting'' regimen (supportive care), irrespective of the platelet count; 79.5% (73.6%) would treat if the platelet counts were <5 × 109/L, 73.5% (67.9%) if < 10, 35.9% (33.6%) if < 20, and 4.2% (2.6%) if <30. Of the treaters, 50.5% would prefer immunoglobulins (Ig), 24.4% glucocorticosteroids (GC), and 20.5% GC and/or Ig. Generally, a rise in platelets, most frequently >50 × 109/L was considered as therapeutic success. In the prospective survey, from the reported 323 children an annual incidence of 2.16 per 100,000 children was calculated. The incidence depended on age and gender, being highest for boys younger than 2 years with 5.8 (girls 3.42) and low with 0.44 for boys (girls 0.89) older than14 years. About 60% of the patients had a preceding infection. Although 83% had a platelet count <20 × 109/L (56% <10 × 109/L), almost all (97.5%) had only mild bleeding symptoms; 2.5% had serious bleeding symptoms requiring blood transfusion or nasal packing, none had ICH, and no death was reported. The mean platelet count on admission was 11.348 (lowest count 8.253) × 109/L. Sixty-one percent received Ig, 19% GC (both either alone or as first choice), 6% Ig plus GC, and 14% no treatment. Side effects were reported in 22% of the children treated with Ig. The retrospective survey mirrored the uncertainty in regard to treatment. The prospective survey provided new aspects on incidence, age, and gender distribution. Although almost all patients had only mild bleeding symptoms, most received Ig and/or GC. The decision to treat depended mainly on the platelet count. From these surveys, conclusions about the effectiveness of treatment cannot be drawn. Recommendations based primarily on platelet counts must be reconsidered.

REFERENCES

  • 1 Sutor A H. Acute immune thrombocytopenia in childhood. Are we treating the platelet count?.  Semin Thromb Hemost . 1998;  24 545-548
  • 2 Medeiros D, Buchanan G R. Idiopathic thrombocytopenic purpura: beyond consensus.  Curr Opin Pediatr . 2000;  12 4-9
  • 3 Nugent D J. Immune thrombocytopenic purpura: why treat?.  <~>[editorial; comment]. J Pediatr . 1999;  134 3-4
  • 4 Gereige R S, Barrios N J. Treatment of childhood acute immune thrombocytopenic purpura with high-dose methylprednisolone, intravenous immunoglobulin, or the combination of both.  P R Health Sci J . 2000;  19 15-18
  • 5 De Mattia D, Del Principe D, Del Vecchio C G. Acute childhood idiopathic thrombocytopenic purpura: AIEOP consensus guidelines for diagnosis and treatment. Associazione Italiana di Ematologia e Oncologia Pediatrica.  Haematologica . 2000;  85 420-424
  • 6 Statistisches Bundesamt. Statistisches Jahrbuch 1998 für die Bundesrepublik Deutschland. Metzler-Poeschel, 1998
  • 7 Sutor A H. Abklärung einer Blutungsneigung.  Hämostaseologie . 2000;  20 1-7
  • 8 Bolton-Maggs P H, Moon I. Assessment of UK practice for management of acute childhood idiopathic thrombocytopenic purpura against published guidelines.  Lancet . 1997;  350 620-623
  • 9 Lilleyman J S. Management of childhood idiopathic thrombocytopenic purpura.  Br J Haematol . 1999;  105 871-875
  • 10 Sutor A H, Gaedicke G. Acute autoimmune thrombocytopenia.  Baillieres Clin Haematol . 1998;  11 381-389
  • 11 Bolton-Maggs P H. Idiopathic thrombocytopenic purpura.  Arch Dis Child . 2000;  83 220-222
  • 12 Pollmann H, Hillemann I, Ritter J. Immune thrombocytopenia.  A diagnostic and therapeutic problem? In: Sutor AH, Thomas KB, eds. Thrombocytopenia in Childhood. New York: Schattauer 1994: 87-93
  • 13 Walker R W, Walker W. Idiopathic thrombocytopenia, initial illness and long term follow up.  Arch Dis Child . 2000;  59 316-322
  • 14 Medeiros D, Buchanan G R. Current controversies in the management of idiopathic thrombocytopenic purpura during childhood.  Pediatr Clin North Am . 1996;  43 757-772
  • 15 Lilleyman J S. Management of childhood idiopathic thrombocytopenic purpura.  Br J Haematol . 1983;  54 11-14
  • 16 Zeller B, Glomstein A, Wesenberg F. [Investigation and treatment of immune thrombocytopenic purpura in children in Norway]. [Norwegian].  Tidsskr Nor Laegeforen . 1996;  116 2157-2159
  • 17 Zaki M, Hassanein A A, Khalil A F. Childhood idiopathic thrombocytopenic purpura: report of 60 cases from Kuwait.  J Trop Pediatr . 1990;  36 10-13
  • 18 Kühne T, Berchtold W, Tran V B, Imbach P. Ethnicity and environment may affect the phenotype of immune thrombocytopenic purpura in children.  Pediatr Res . 2000;  48 374-379
  • 19 Bedri A, Abebe E. Idiopathic thrombocytopenic purpura (ITP) in Ethiopian children: clinical findings and response to therapy.  Ethiop Med J . 1995;  33(2) 75-81
  • 20 George J N, Raskob G E. Idiopathic thrombocytopenic purpura: a concise summary of the pathophysiology and diagnosis in children and adults.  Semin Hematol . 1998;  35 (Suppl 1) (5-8)
  • 21 Karpatkin S. Autoimmune (idiopathic) thrombocytopenic purpura.  Lancet . 1997;  349 1531-1536
  • 22 Höcker-Schulz S, Elstner T, Pawlosky J, Gadner H. Use of corticosteroids and immunoglobulins in acute and chronic immune thrombocytopenia in childhood. A clinically oriented treatment concept. [German].  Klin Pädiatr . 1997;  209 30-35
  • 23 Hedman A, Henter J I, Hedlund I, Elinder G. Prevalence and treatment of chronic idiopathic thrombocytopenic purpura of childhood in Sweden.  Acta Paediatr . 1997;  86 226-227
  • 24 Zeller B, Helgestad J, Hellebostad M. Immune thrombocytopenic purpura in childhood in Norway: a prospective, population-based registration.  Pediatr Hematol Oncol . 2000;  17 551-558
  • 25 Sutor A H, von Kries R, Cornelissen E A. Vitamin K deficiency bleeding (VKDB) in infancy. ISTH Pediatric/Perinatal Subcommittee; International Society on Thrombosis and Haemostasis.  Thromb Haemost . 1999;  81 456-461
  • 26 Hsiao C C. Epstein-Barr virus associated with immune thrombocytopenic purpura in childhood: a retrospective study.  J Paediatr Child Health . 2000;  36 445-448
  • 27 Lusher J M, Zuelzer W W. Idiopathic thrombocytopenic purpura in childhood.  J Pediatr . 1966;  68 971-979
  • 28 Gaedicke G, Imbach P, Kleihauer E. The place of intravenous immunoglobulin (IgG iv) therapy in thrombocytopenia.  Blut . 1984;  48 409-413
  • 29 Fujisawa K, Iyori H, Ohkawa H. A prospective, randomized trial of conventional, dose-accelerated corticosteroids and intravenous immunoglobulin in children with newly diagnosed idiopathic thrombocytopenic purpura.  Int J Hematol . 2000;  72 376-383
  • 30 Imbach P, Kuhne T. Immune thrombocytopenic purpura ITP.  Vox Sang . 1998;  74 (Suppl 2) (309-314)
  • 31 Neau D, Bonnet F, Michaud M. Immune thrombocytopenic purpura after recombinant hepatitis B vaccine: retrospective study of seven cases.  Scand J Infect Dis . 1998;  30 115-118
  • 32 Medeiros D, Buchanan G R. Major hemorrhage in children with idiopathic thrombocytopenic purpura: immediate response to therapy and long-term outcome.  J Pediatr . 1998;  133 334-339
  • 33 Lee M S, Kim W C. Intracranial hemorrhage associated with idiopathic thrombocytopenic purpura: report of seven patients and a meta-analysis.  Neurology . 1998;  50 1160-1163
  • 34 Modak S I, Bussel J B. Treatment of children with immune thrombocytopenic purpura: are we closer to resolving the dilemma?.  J Pediatr . 1998;  133 313-314
  • 35 Dickerhoff R, Von Ruecker A. The clinical course of immune thrombocytopenic purpura in children who did not receive intravenous immunoglobulins or sustained prednisone treatment.  J Pediatr . 2000;  137 629-632
  • 36 Sutor A H. Thrombozytenzählung bei Thrombozytopenie (Platelet count in thrombocytopenia).  Pädiatr Prax . 1995;  50 43-52
  • 37 Kühne T, Berchtold W, Tran V B, Imbach P. Ethnicity and environment may affect the phenotype of immune thrombocytopenic purpura in children.  Pediatr Res . 2000;  48 374-379
  • 38 Bolton-Maggs P H. Acute idiopathic thrombocytopenic purpura-management in childhood [letter; comment].  Blood . 1997;  89 1465
  • 39 Sundblad A, Ferreira C, Nobrega A. Characteristic generated alterations of autoantibody patterns in idiopathic thrombocytopenic purpura.  J Autoimmun . 1997;  10 193-201
  • 40 Gaydos L A, Freireich E J, Mantel N. The quantitative relation between platelet count and hemorrhage in patients with acute leukemia.  N Engl J Med . 1962;  266 905-913
  • 41 Kühne T. Hämorrhagische Diathese bei Störungen der primären Hämostase.  Hämostaseologie . 2000;  20 1-82
  • 42 Springer W, von Rücker A. Difficulties in determining prophylactic transfusion thresholds of platelets in leukemia patients.  Blood . 2000;  92 2183-2184
  • 43 Baronci C, Petrone A, Miano C. Treatment of acute idiopathic thrombocytopenic purpura in children. A retrospective evaluation of 120 cases.  Ann Ist Super Sanita . 1998;  34 457-461
  • 44 Corrigan Jr J J. Treatment dilemma in childhood idiopathic thrombocytopenic purpura [comment].  Lancet . 1997;  350 602-603
  • 45 Vesely S, Buchanan G R, Cohen A, Raskob G, George J. Self-reported diagnostic and management strategies in childhood idiopathic thrombocytopenic purpura: results of a survey of practicing pediatric hematology/oncology specialists.  J Pediatr Hematol Oncol . 2000;  22 55-61
  • 46 Kattamis A C, Shankar S, Cohen A R. Neurologic complications of treatment of childhood acute immune thrombocytopenic purpura with intravenously administered immunoglobulin G.  J Pediatr . 1997;  130 281-283
  • 47 Ferrara M, Ponte D, Napoli G. Adverse reactions after ITP treatment with high dose of intravenous Ig.  Blood . 2000;  92 (Suppl) (84b-84b)
  • 48 Scaradavou A, Woo B, Woloski B M. Intravenous anti-D treatment of immune thrombocytopenic purpura: experience in 272 patients.  Blood . 1997;  89 2689-2700
  • 49 Jayabose S, Mahmoud M, Levendoglu-Tugal O. Corticosteroid prophylaxis for neurologic complications of intravenous immunoglobulin G therapy in childhood immune thrombocytopenic purpura.  J Pediatr Hematol Oncol . 1999;  21 514-517
  • 50 Kurzeia A KR. Aseptische Meningitis nach iv Immunoglobulingabe.  Pädiatr Praxis . 1998;  55 629-632
  • 51 Gaines A R. Acute onset hemoglobinemia and/or hemoglobinuria and sequelae following Rh(o)(D) immune globulin intravenous administration in immune thrombocytopenic purpura patients.  Blood . 2000;  95 2523-2529
  • 52 Sutor A H, Bergstraesser E, Kaufmehl K. Drop of leukocytes after treatment with immunoglobulins in children with acute immune thrombocytopenia (ITP).  Eur J Pediatr . 1999;  158 (Suppl 2) (219-219)
  • 53 Berkovitch M, Dolinski G, Tauber T, Aladjem M, Kaplinsky C. Neutropenia as a complication of intravenous immunoglobulin (IVIG) therapy in children with immune thrombocytopenic purpura: common and non-alarming.  Int J Immunopharmacol . 1999;  21 411-415
  • 54 George J N, Woolf S H, Raskob G E. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology.  Blood . 1996;  88 3-40
  • 55 Buchanan G R, de Alarcon A P, Feig S A. Acute idiopathic thrombocytopenic purpura-management in childhood.  Blood . 1997;  89 1464-1465
  • 56 Windrum P, Barucha C, Desai Z R. Intravenous immunoglobulin therapy and renal dysfunction.  Br J Haematol . 1998;  101 592-596
  • 57 Comenzo R L, Malachowski M E, Meissner H C, Fulton D R, Berkman E M. Immune hemolysis, disseminated intravascular coagulation, and serum sickness after large doses of immune globulin given intravenously for Kawasaki disease.  J Pediatr . 2000;  120 926-928
  • 58 Reinhardt W H, Berchtold P E. Effect of high-dose immunoglobulin therapy on blood rheology.  Lancet . 1992;  339 662-664
  • 59 McColl M D, Omran A, Walker I D, Lowe G D. Acute renal failure complicating high-dose intravenous immunoglobulin therapy for acquired haemophilia.  Haemophilia . 1999;  5 124-126
  • 60 Tsiouris J, Tsiouris N. Hemiplegia as a complication of treatment of childhood immune thrombocytopenic purpura with intravenously administered immunoglobulin [letter].  J Pediatr . 1998;  133 717
  • 61 Savasan S, Tuzcu V, Warrier I, Karpawich P. Cardiac rhythm abnormalities during intravenous immunoglobulin G infusion for treatment of thrombocytopenia.  J Pediatr Hematol Oncol . 1997;  19 254-257
  • 62 Blanchette V S, Luke B, Andrew M. A prospective, randomized trial of high-dose intravenous immune globulin G therapy, oral prednisone therapy, and no therapy in childhood acute immune thrombocytopenic purpura.  J Pediatr . 1993;  123 989-995
  • 63 Kühne T, Freedman J, Semple J W. Platelet and immune responses to oral cyclic dexamethasone therapy in childhood chronic immune thrombocytopenic purpura.  J Pediatr . 1997;  130 17-24
  • 64 Mall V, Thomas K B, Sauter S. Effect of glucocorticoids, Ecoli and Erwinia L-asparaginase on hemostatic proteins in children with acute lymphoblastic leukemia.  Klinische Pädiatrie . 1999;  211 205-210
  • 65 Ozsoylu S, Sayli T R, Ozturk G. Oral megadose methylprednisolone versus intravenous immunoglobulin for acute childhood idiopathic thrombocytopenic purpura.  J Pediatr Hematol Oncol . 1993;  10 317-321
  • 66 Eden O B, Lilleyman J S. Guidelines for management of idiopathic thrombocytopenic purpura. The British Paediatric Haematology Group.  Arch Dis Child . 1992;  67 1056-1058
  • 67 Imbach P. A multicenter European trial of intravenous immune globulin in immune thrombocytopenic purpura in childhood.  Vox Sang . 1985;  49 (Suppl 1) (25-31)
  • 68 Cripe T P. Idiopathic thrombocytopenic purpura: reasons to resolve the chaos.  J Pediatr Hematol Oncol . 1999;  21 465-466
  • 69 George J N, Woolf S H, Raskob G E. Idiopathic thrombocytopenic purpura: a guideline for diagnosis and management of children and adults. American Society of Hematology.  Ann Med . 1998;  30 38-44
  • 70 Bocher A, Hagmann F G, Kreiter H. Chronic idiopathic thrombocytopenic purpura. Current therapy concept and introduction to pathophysiologic, clinical and diagnostic aspects.  Med Klin [in German]. 1998;  93 707-718
  • 71 Mazzucconi M G, Arista M C, Peraino M. Long-term follow-up of autoimmune thrombocytopenic purpura (ATP) patients submitted to splenectomy.  Eur J Haematol . 1999;  62 219-222
  • 72 Kühne T, Egli D, Imbach P. Epidemiology of childhood immune thrombocytopenic purpura in a defined area in Europe, and rational and profile of a intercontinental ITP registry.  Blood . 1997;  90 (Suppl) (Abst 3090)
  • 73 Sutor A H, Dickerhoff R, Gaedicke G, Pollmann H. Akute postinfektiöse Immunthrombozytopenie (ITP) im Kindesalter. In: Reinhard D, Creutzig U, Kiess W, eds. Leitlinien Kinderheilkunde und Jugendmedizin Munich: Urban and Fischer 1999: 23-27
    >